Latest Conference Articles

A panel discussion at the Community Oncology Alliance (COA) Payer Exchange Summit highlighted the tension between state regulation of pharmacy benefit managers (PBMs) and the Employee Retirement Income Security Act (ERISA) preemption, emphasizing the need for reforms to balance employer uniformity with addressing PBM practices.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses exciting developments in HER2-targeted therapies that he foresees making a difference in the treatment of non–small cell lung cancer (NSCLC).

There are concerns that the negotiated drug prices under the Inflation Reduction Act (IRA) are leading to large provider reimbursement cuts, explained Nick Ferreyros, managing director, Community Oncology Alliance.

Sulthiame demonstrated significant reductions in respiratory pauses and improvements in oxygen levels during sleep, offering hope for patients with obstructive sleep apnea who cannot use continuous positive airway pressure machines.

Panelists at the Community Oncology Alliance Payer Exchange Summit 2024 agreed that overcoming health care challenges will depend heavily on collaboration and active engagement from multiple stakeholders in the policy and regulatory process.

Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, details exciting findings from the EMPOWER-Lung 1 trial regarding cemiplimab and patients with non–small cell lung cancer (NSCLC).

Eva Otter, president of Pulmonary Hypertension Association Europe, discusses the significance of shared decision-making for patients with pulmonary arterial hypertension.

Data presented in the second Presidential Symposium at the 2024 World Conference on Lung Cancer showed encouraging responses to novel agents among patients with HER2-mutated non–small cell lung cancer (NSCLC).

Samyukta Mullangi, MD, MBA, medical director at Thyme Care, explained her excitement to meet with industry leaders, share best practices, and learn about new innovations in oncology care at Patient-Centered Oncology Care® (PCOC) 2024.

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for severe asthma and dupilumab for pediatric asthma.

Research presented at the 2024 European Society of Cardiology Congress explored gender-based care and outcomes disparities, with potential implications for health care policy and equitable care of women and men in secondary disease prevention.

New findings highlight the potential role of artificial intelligence in supporting health care professionals, but thorough testing is needed before its integration into everyday clinical practice.

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, shares findings from the FLAME trial on blood eosinophil changes in patients with chronic obstructive pulmonary disorder.

Wanda Phipatanakul, MD, MS, professor of pediatrics at Harvard Medical School and director of the Clinical Research Center at Boston Children's Hospital, discusses some of the most significant health disparities impacting respiratory care.

Lung cancer screening experts from around the globe delivered strategies and best practices for improving access to screening and facilitating earlier detection at the 2024 World Conference on Lung Cancer.

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of pembrolizumab, but results presented at the 2024 World Conference on Lung Cancer could shake up that status quo.

Io Hui, PhD, researcher at The University of Edinburgh, discusses how artificial intelligence (AI) is being applied in respiratory care for both clinicians and patients.

A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).

There are general risk factors for patients with rheumatic disease developing interstitial lung disease, but there are also disease-specific risk factors depending on which rheumatic disease they have, explained Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital.

Speakers at the European Respiratory Society Congress 2024 highlighted the potential of artificial intelligence (AI) in transforming respiratory health care, while also raising important ethical concerns related to autonomy, equity, transparency, and sustainability.

The Center on Health Equity & Access provides the latest news, research, and expert opinions on the state of equity in health care.

Susan Sabo-Wagner, MSN, RN, OCN, of the American Oncology Network, expressed excitement toward networking, innovative discussions, and panels on patient advocacy at Patient-Centered Oncology Care® (PCOC) 2024.

The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer. Sandip Patel, MD, joined for an interview looking forward to the unique features of this year's meeting.

The 2024 World Conference on Lung Cancer (WCLC), meeting in San Diego, California, from September 7 to 10, 2024, will feature practice-changing data and discussion in the lung cancer space.

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

The FINEARTS-HF late-breaking data were forefront at the 2024 European Society of Cardiology Congress in London.

The European Respiratory Society (ERS) Congress 2024 will delve into the balance between human expertise and the growing role of artificial intelligence (AI) in respiratory medicine.